Brain Tumour Research

Recent papers from Brain Tumour Research

1. TRIM24 cooperates with CDKN2A deletion to drive astrocyte malignant transition by reprogramming mevalonate metabolismActa Neuropathologica Communications · 2026
2. A PDGFRB-CD44-MIF crosstalk promotes cancer-associated cellular phenotypes in ATRT-TYR/MYC cell linesFrontiers in Oncology · 2026
3. 16 Computational dissection of invasive glioblastoma reveals druggable and regulatory targetsNeuro-Oncology · 2026
4. 53 Analysis of translational challenges across 19 brain tumour therapeutic development programmes: Insights from the BTR-NTA acceleratorNeuro-Oncology · 2026
5. 109 Multi-omic integration reveals intra-tumour heterogeneity and identifies disulfiram and copper as a synergistic therapy in paediatric ependymomaNeuro-Oncology · 2026
6. 129 Electroactive drug delivery for local glioblastoma treatmentNeuro-Oncology · 2026
7. Development of an age specific EORTC questionnaire to assess the health-related quality of life (HRQOL) of children with cancer aged 8–14 years – a mixed-methods content elicitation phase I & II EORTC QLG studyEuropean Journal of Cancer · 2026
8. Firefox, a protein encoded by circular PVT1 , is essential for MYC-driven oncogenesisGenes & Development · 2026
9. Honeybadger, a micropeptide encoded by an alternative PVT1 transcript, is a critical negative regulator of RAS–MAPK signaling in MYC-driven tumorsGenes & Development · 2026
10. Glial brain tumors in pediatric patients with germline biallelic variation in the MBD4 gene: Expanding the spectrum of MBD4 -associated neoplasia syndrome (MANS)Neuro-Oncology Practice · 2026
11. Pediatric ependymoma in the molecular era: real-world experience with diagnostic correlation and long-term clinical outcomesJournal of Neuro-Oncology · 2026
12. Global Burden and Temporal Trends of Brain and Central Nervous System Tumors in Children and Adolescents: A Systematic Analysis for the Global Burden of Disease Study 2021Cancer Innovation · 2026
13. Single-cell multi-omic analyses resolve the cellular diversity of ALK/ROS1/MET/NTRK-fused gliomas in infants and older children2026
14. BRAF Inhibition in Congenital Nevi and Neural MelanosisJAMA Dermatology · 2026
15. Tumor-Targeted pan-RAS Inhibition as a Novel Biologic Therapy for Diffuse Midline GliomaNeuro-Oncology · 2026
16. Advances in the management of pediatric low-grade gliomaNeurotherapeutics · 2026
17. ID #1162 Oncogenic ALK and ROS1 fusions converge on STAT3 activation and stall neural differentiation in infant-type hemispheric gliomaNeuro-Oncology Pediatrics · 2026
18. Id #933 outcomes of Infants and Young Children With Newly Diagnosed Central Nervous System (Cns) Embryonal Tumors Other Than Medulloblastoma and Atypical Teratoid/Rhabdoid Tumor (At/Rt), Including Embryonal Tumor With Multi-Layered Rosettes (Etmr), Pineoblastoma (Pb) and CNS Embryonal Tumors Nos, Treated on the “Head Start” 4 ProtocolNeuro-Oncology Pediatrics · 2026
19. ID #950 CURE-ETMR, a Prospective, International, Molecularly Guided Trial Utilizing Centralized Screening and Risk-Adapted Assignment for Infants with Rare Embryonal Brain TumorsNeuro-Oncology Pediatrics · 2026
20. ID #582 Therapeutic Patterns and Outcomes of Craniopharyngioma in Early Childhood: A Canadian Multicenter Registry StudyNeuro-Oncology Pediatrics · 2026